『How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide』のカバーアート

How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide

How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
#Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLossHow long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot.Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS00:00 Why "it's gone in 5 days" is wrong01:26 What tirzepatide is and how it works02:25 Half-life explained02:59 Why it lasts so long: albumin binding03:48 Clock 1: the 7-day clock04:18 Side effects: when they hit and how to ease them05:47 Why food noise returns at the end of the week06:14 Missed a dose? The 96-hour rule07:16 Clock 2: the 4-week clock and steady state08:06 Why your dose goes up in 2.5 mg steps09:05 Birth control: the 4-week rule10:09 Clock 3: how long tirzepatide stays in your system10:56 What makes clearance faster or slower12:39 Why severe side effects don't stop when you stop13:42 Surgery, colonoscopy and sedation15:07 Pregnancy planning15:35 Will it show up on a drug test?16:12 Clock 4: what happens when you stop16:46 Why your body fights weight loss17:36 SURMOUNT-4: stopping vs staying on17:58 My own weight-regain story18:48 The muscle problem19:51 The plan: 2 good paths21:17 Protecting your muscle on GLP-1sREFERENCESEli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdfKindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltextAmerican Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperativeAronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicineDeacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765.Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません